Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
74 hedge funds and large institutions have $1.01B invested in Prometheus Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 34 increasing their positions, 5 reducing their positions, and 4 closing their positions.
10,910% more call options, than puts
Call options by funds: $7.38M | Put options by funds: $67K
580% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 5
575% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
76% more capital invested
Capital invested by funds: $573M → $1.01B (+$434M)
45% more funds holding
Funds holding: 51 → 74 (+23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$38.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.64M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$6.68M |
| 5 |
FAM
Fred Alger Management
New York
|
+$5.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
-$34.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.8M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$11.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.23M |
| 5 |
PA
Perceptive Advisors
New York
|
-$4.42M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Adage Capital Partners
Boston,
Massachusetts
| – | -$8.23M | -347,315 | Closed |
|
|
LP
77
LMR Partners
London,
United Kingdom
| – | -$1.19M | -50,000 | Closed |
|
|
E
78
Ergoteles
New York
| – | -$208K | -8,791 | Closed |
|
RXDX Hedge Fund Activity: Q4 2021 in Review
74 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q4 2021, worth a combined $1.01B — up 76% from $573M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RXDX positions and 4 closed out — a net gain of 23 holders — while 34 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $38.2M. The largest seller was CHI Advisors, cutting an estimated $34.7M.
- 74 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q4 2021, up from 51 in Q3 2021.
- Funds reported $1.01B of Prometheus Biosciences, Inc. Common Stock stock for Q4 2021, up 76% quarter-over-quarter.
- 27 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +23 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $38.2M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q4 2021 was CHI Advisors, an estimated $34.7M sold.
Based on aggregated 13F filings for Q4 2021.